8-KLeadership ChangesExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Apr 5, 2022)

Filed April 5, 2022For Securities:ALNY

Summary

This 8-K filing by Alnylam Pharmaceuticals, Inc. announces the resignation of Dr. Steven M. Paul from its Board of Directors, effective April 16, 2022. The company states that Dr. Paul's departure is not due to any disagreements regarding company operations, policies, or practices. Concurrent with his resignation, the Board's size will be reduced from eleven to ten members. Following Dr. Paul's departure, Colleen F. Reitan will join the People, Culture and Compensation (PC&C) Committee, while Amy W. Schulman and Olivier Brandicourt will continue their roles on the committee.

Key Highlights

  • 1Dr. Steven M. Paul is resigning from the Board of Directors effective April 16, 2022.
  • 2The resignation is stated to be voluntary and not a result of any disagreements with the Company.
  • 3The size of the Board of Directors will be reduced from eleven to ten members upon Dr. Paul's resignation.
  • 4Colleen F. Reitan will be appointed to the People, Culture and Compensation (PC&C) Committee.
  • 5Amy W. Schulman will continue as Chair of the PC&C Committee.
  • 6Olivier Brandicourt will continue as a member of the PC&C Committee.
  • 7A press release regarding Dr. Paul's retirement was issued on April 5, 2022.

Frequently Asked Questions

The filing states that Dr. Paul informed the Board of his resignation, and it was not caused by any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The press release refers to this as his retirement.

The Board's size is being reduced from eleven to ten members. This is a minor adjustment and the filing indicates it was approved following the recommendation of the Nominating and Corporate Governance Committee, suggesting it's a standard governance practice.

Upon Dr. Paul's resignation, Colleen F. Reitan will join the committee. Amy W. Schulman will remain as Chair, and Olivier Brandicourt will continue as a member.

This filing does not report any direct financial impact or severance arrangements related to Dr. Paul's resignation. It primarily concerns board composition changes.